10 Best Building Product Stocks To Buy For 2014

DELAFIELD, Wis. (Stockpickr) — At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend — a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

10 Best Building Product Stocks To Buy For 2014: Euro/Forint(GY)

GenCorp Inc. engages in the manufacture and sale of aerospace and defense products and systems in the United States. The company operates in two segments, Aerospace and Defense, and Real Estate. The Aerospace and Defense segment offers defense system products, including liquid, solid, and air-breathing propulsion systems and components for applications in missile defense systems, maneuvering propulsion systems, precision war-fighting systems, and specialty metal products, as well as for use in strategic, tactical, and precision strike missiles. This segment also provides composite and metallic aerospace structural components, and warhead and armament systems for precision tactical and long range weapon applications. In addition, it provides liquid, solid, and electric propulsion systems and components for space systems, such as expendable and reusable launch vehicles, transatmospheric vehicles, manned and unmanned spacecraft, separation and maneuvering systems, upper stage engines, satellites, solid boosters, and integrated propulsion subsystems. This segment serves military, civil, and commercial space customers; Department of Defense; National Aeronautics and Space Administration; aerospace, defense, and commercial prime contractors; and various agencies of the United States government. The Real Estate segment engages in the re-zoning, entitlement, sale, and leasing of the company?s excess real estate assets; and owns approximately 12,200 acres of land in the Sacramento metropolitan area. GenCorp Inc. was founded in 1915 and is headquartered in Rancho Cordova, California.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Equities Trading DOWN
    Shares of GenCorp (NYSE: GY) were down 3.97 percent to $17.86 after the company reported Q1 results. GenCorp reported a Q1 loss of $0.03 per share.

  • [By Jake L’Ecuyer]

    Equities Trading DOWN
    Shares of GenCorp (NYSE: GY) were down 5.16 percent to $17.64 after the company reported Q1 results. GenCorp reported a Q1 loss of $0.03 per share.

  • [By Jon C. Ogg]

    Short sellers are an interesting lot. They may be betting against the market or against a specific stock, but they are a necessary and useful aspect required for most markets. GenCorp Inc. (NYSE: GY) is a stock that 24/7 Wall St. recently featured as one of nine stocks that could double in 2014. This comes with many risks and caveats, and it also is in direct competition with a massive number of short sellers.

10 Best Building Product Stocks To Buy For 2014: Endologix Inc(ELGX)

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. It offers the ELG System, a stent graft and delivery system for the treatment of abdominal aortic aneurysms through minimally-invasive endovascular repair. The company also provides aortic extensions and limb extensions, which attach to the main body of ELG Device, enabling physicians to customize it to fit the patient?s anatomy. In addition, it offers accessories, such as guidewires, snares, and catheter introducer sheaths that facilitate the optimal delivery of its ELG Device. Endologix, Inc. sells its products through direct sales force and independent distributors in the United States, Europe, Asia, South America, and Mexico. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Advisors’ Opinion:

  • [By DailyFinance Staff]

    Concerns about the political uncertainty in Ukraine caused some volatility in the markets Friday afternoon, with the major indexes making several U-turns ahead of the weekend. The Dow Jones industrial average (^DJI), which had been up by as much as 125 points, briefly dropped into loss territory before rebounding to end 49 points higher. The Standard & Poor’s 500 index (^GPSC) edged up 5 points, adding to Thursday’s record high, but the Nasdaq composite (^IXIC) lost 10 points. AP/Darko VojinovicPro-Russian militias have seized local government buildings in Crimea, Ukraine; the unrest there is making investors around the world nervous. February was a great month for investors. All three major averages jumped by about 4 percent. UnitedHealth Group (UNH) led the blue chips, gaining 1½ percent. Other health providers – Aetna (AET), Wellpoint (WLP), Cigna (CI) and Humana (HUM) — all gained between 1½ and 2 percent. And retail stocks remained active. Target (TGT) added another 3 percent. Best Buy rose 4 percent, and Fred’s (FRED), a regional department store chain, jumped 10 percent. But Pier 1 (PIR) fell 5½ percent after lowering its earnings outlook for a second time. That led to a series of brokerage downgrades. Decker Outdoor (DECK) tumbled 12 percent. The maker of footwear brands such as Ugg and Teva issued a weak outlook. And apparel maker Lululemon (LULU) fell 5-percent on negative comments from Credit Suisse. It seems as though there are always some big movers in the drug and biotech sectors – and that was certainly the case today. GW Pharmaceuticals (GWPH) rose 2 percent after the FDA granted orphan status to its drug to treat a rare form of childhood epilepsy. But most of the action was on the downside. Endologix (ELGX) slid 24 percent after forecasting lower revenue growth. Questcor (QCOR) fell 10 percent. It’s lost big for three straight days amid allegations of questionable business practices. Jazz Pharma

  • [By John Kell]

    Medical device maker Endologix Inc.(ELGX) issued targets for the new year that fell short of Wall Street’s expectations, pushing shares down 23% to $13.75 premarket.

10 Best Building Product Stocks To Buy For 2014: Hillenbrand Inc(HI)

Hillenbrand, Inc. designs, manufactures, distributes, and sells funeral service products to licensed funeral directors operating licensed funeral homes. The company?s products include burial caskets, cremation caskets, containers, vaults, urns, and selection room display fixturing for funeral homes, as well as other personalization and memorialization products and services, including Web-based applications, and the creation and hosting of Websites for licensed funeral homes. It markets its products under the Batesville and Options brand name through direct sales force in the United States, Puerto Rico, Canada, Mexico, the United Kingdom, and Australia. The company also designs, produces, markets, sells, and services bulk solids material handling equipment and systems for various industrial markets, including plastics, food, chemicals, pharmaceuticals, power generation, coal mining, pulp and paper, frac sand, industrial minerals, agribusiness, recycling, wood and forest pr oducts, and biomass energy generation. It offers feeders and pneumatic conveying equipment under the K-Tron brand name; and size reduction equipment, such as hammer mills, double-roll crushers, wood and bark hogs, chip sizers, screening equipment, pneumatic and mechanical conveying systems, storage/reclamation systems, and specialty crushers and other equipment under the Pennsylvania Crusher, Gundlach, and Jeffrey Rader brand names. In addition, the company manufactures dry material separation machines that sort dry, granular products based on the particle?s size serving various industries, including frac sand, potash, urea, phosphates, chemical, agricultural, plastics, and food processing. The company sells its material handling equipment and systems worldwide through a combination of a direct sales force, and a network of independent sales representatives and distributors. Hillenbrand, Inc. was founded in 2008 and is headquartered in Batesville, Indiana.

Advisors’ Opinion:

  • [By Laura Brodbeck]

    Tuesday

    Earnings Expected: Buffalo Wild Wings, Inc. (NASDAQ: BWLD), Hillenbrand Inc (NYSE: HI), Sirius XM Holdings Inc. (NASDAQ: SIRI) Economic Releases Expected: German retail sales, French consumer confidence, German unemployment rate, eurozone CPI, eurozone PPI, US trade balance, US redbook

    Wednesday

  • [By GURUFOCUS]

    Hillenbrand Inc. (HI), a diversified industrial company, makes and sells business-to-business products and services for various industries worldwide. Dec. 4, the company increased is quarterly dividend 1.3% to $0.1975 per share. the dividend is payable Dec. 31, 2013, to shareholders of record at the close of business on Dec. 17, 2013. The yield based on the new payout is 2.8%.

10 Best Building Product Stocks To Buy For 2014: HealthSouth Corporation (HLS)

HealthSouth Corporation offers inpatient rehabilitative healthcare services in the United States and Puerto Rico. The company primarily operates inpatient rehabilitation hospitals and long-term acute care hospitals, which provide treatment on both an inpatient and outpatient basis. Its inpatient rehabilitation hospitals offer services to patients who require institutional rehabilitation care, and patient care is provided by nursing and therapy staff as directed by a physician order. As of December 31, 2010, the company operated 97 inpatient rehabilitation hospitals, including 68 owned hospitals and 29 jointly owned hospitals; 6 freestanding long-term acute care hospitals; 32 outpatient rehabilitation satellite clinics; 25 licensed hospital-based home health agencies; and managed 4 inpatient rehabilitation units through management contracts. The company was founded in 1983 and is headquartered in Birmingham, Alabama.

Advisors’ Opinion:

  • [By Brad Thomas]

    As the only healthcare REIT with a "hospital-focused" platform, MPW is a relatively new REIT that was formed (in 2004) to lease from many of the nation’s leading hospital operators, including Prime Healthcare Services, Kindred Healthcare (KND), HealthSouth (HLS), Health Management Associates (HMA), Community Health Systems (CYH), Vibra Healthcare, Ernest Health Inc., and IASIS Healthcare.

  • [By Rich Duprey]

    Rehab hospital operator HealthSouth (NYSE: HLS  ) announced this morning its second-quarter dividend on its 6.5% Series A convertible perpetual preferred stock of $16.25 per share.

10 Best Building Product Stocks To Buy For 2014: Super Micro Computer Inc.(SMCI)

Super Micro Computer, Inc., together with its subsidiaries, develops and provides high performance server solutions based on modular and open-standard architecture. The company offers a range of rackmount, workstation, storage, graphic processing unit, and blade server systems, as well as subsystems and accessories used by distributors, original equipment manufacturers, and end customers to assemble server systems. It provides server options with single, dual, and quad CPU capability supporting Intel Pentium and Xeon multi-core architectures; and server systems based on AMD dual and quad Opteron. The company also offers server subsystems and accessories, including server boards, and chassis and power supplies. In addition, it sells other system accessories, such as microprocessors, memory, and disc drives. The company sells its server systems, and server subsystems and accessories through distributors, including value added resellers, system integrators, and original equip ment manufacturers, as well as through its direct sales force primarily in the United States, Europe, and Asia. Super Micro Computer, Inc. was founded in 1993 and is headquartered in San Jose, California.

Advisors’ Opinion:

  • [By Lauren Pollock]

    Super Micro Computer Inc.’s(SMCI) fiscal second-quarter profit more than doubled as the servers maker reported a double-digit jump in sales and higher gross margins. The latest results topped Super Micro’s expectations and the company issued a rosy outlook for the fiscal third quarter. Shares surged 12% to $20.79 premarket.

  • [By Seth Jayson]

    Super Micro Computer (Nasdaq: SMCI  ) reported earnings on April 23. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 31 (Q3), Super Micro Computer missed estimates on revenues and beat expectations on earnings per share.

10 Best Building Product Stocks To Buy For 2014: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company’s product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company’s program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company’s RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company’s lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company’s lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatmen t of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company’s lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company’s arrangement with DoD supporting the development of the Company’s Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrange ment. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company’s anti-viral therapeutic programs use the Company’s translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company’s translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA’s Animal Rule. The Co mpany’s lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company’s lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD’s invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exp osure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company’s anti-viral therapeutic programs are also focused on the development of the Company’s product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company’s lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company pau sed its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company’s PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors’ Opinion:

  • [By Leo Sun]

    Prosensa: GSK doesn’t believe in it — so why should you?
    Throughout 2013, Prosensa and its former partner GlaxoSmithKline competed against Sarepta Therapeutics (NASDAQ: SRPT  ) to launch the first dedicated treatment for Duchenne muscular dystrophy (DMD).

  • [By Ernie Tremblay, Biosciences Specialist, Money Morning | January 17, 2014 · ]

    When I’m setting out in search of a lucrative bioscience stock, here are some qualities I find really attractive:

    Market cap. $250M-$2.5B. This is the sweet spot for growth. Less than $250M can mean low volume trading, which can be a problem if you need to sell. More than $2.5B makes a company less responsive to catalysts. Single product pipeline. These companies can yield high returns because they carry high risk. If their drug succeeds, their investors can get rich rapidly. A failure, however, can mean doom, so you need to know what you’re doing in evaluating the drug’s potential to be effective, safe, convincing to the FDA, and marketable. Some of my recommendations, of course, are for companies that have richer pipelines. They yield less return, but they’re safer bets for a balanced portfolio. An upcoming catalyst. A catalyst, such as an AdCom, FDA approval date (called a PDUFA), or even results from a clinical trial, can make you a whole lot richer overnight. Last year, Sarepta Therapeutics (Nasdaq: SRPT) tripled its stock price overnight when the company announced positive results for a study of its Duchenne muscular dystrophy drug. Orphan drug status. As I explained above, these drug candidates have real advantages over traditional “blockbuster” entries. An extreme need. Everyone born with HoFH would eventually die from it, and before Aegerion’s Juxtapid (lomitapide), no effective treatment existed. Patients were longing for it. Little or no competition. ISIS Pharmaceuticals Inc. (Nasdaq: ISIS), in partnership with Genzyme Pharmaceuticals, was developing a drug, mimoperson, to compete with Juxtapid, but it was inferior in several ways (injectable rather than oral, more severe side effects). It also passed its AdCom, but barely, garnering a vote of 9 to 6. Juxtapid had a nearly clear field to play in. The Profits Ahead

    Next, of course, comes the tricky part. You’ve got to be able to read studies on exper

  • [By Sean Williams]

    Today, we’re going to take a closer look at Sarepta Therapeutics’ (NASDAQ: SRPT  ) presentation, which was delivered Wednesday by President and CEO Chris Garabedian.

10 Best Building Product Stocks To Buy For 2014: Palatin Technologies Inc. (PTN)

Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.

Advisors’ Opinion:

  • [By James E. Brumley]

    For the third time in a little more than three months I find myself singing the praises of Palatin Technologies, Inc. (NYSEMKT:PTN), suggesting it is a “buy” … at least to nimble and cautious speculators. It’s a rarity, as I tend not to like beating a dead horse (personal preference). PTN, however, is one of those rare cases where the message deserves to be delivered again, as there’s still a lot of opportunity left for newcomers to tap into.

  • [By James E. Brumley]

    At first glance, Palatin Technologies, Inc. (NYSEMKT:PTN) doesn’t look like anything particularly special, nor anything particularly investment-worthy. The longer you study the chart of PTN, however, the clearer it becomes… this stock is on the verge of breaking out, and should be on most traders’ watchlists.

10 Best Building Product Stocks To Buy For 2014: Steinway Musical Instruments Inc. (LVB)

Steinway Musical Instruments, Inc., through its subsidiaries, designs, manufactures, markets, and distributes musical instruments in the United States and internationally. The company operates in two segments, Pianos and Band & Orchestral Instruments. The Pianos segment offers pianos under Steinway & Sons, Boston, and Essex brands; and engages in online music retailing business. This segment sells its products to professional artists and amateur pianists, and institutions through independent dealers primarily in the United States, Germany, Austria, Switzerland, the United Kingdom, France, and Italy. It operates six retail showrooms in the United States and five retail showrooms in Europe. The Band & Orchestral Instruments segment manufactures and sells piccolos, flutes, clarinets, oboes, bassoons, trumpets, French horns, tubas, and trombones, as well as intermediate and professional level woodwind and brass instruments under Bach, Selmer, Selmer Paris, C.G. Conn, Leblanc, King, Armstrong, Holton, Yanagisawa, Vito, Emerson, Avanti, Noblet, Artley, and Benge brands; distributes saxophones and clarinets; manufactures and distributes acoustical and tuned percussion instruments, including outfit drums, marching drums, concert drums, marimbas, xylophones, vibraphones, orchestra bells, and chimes; distributes violins, violas, cellos, and basses under Glaesel, Scherl & Roth, and William Lewis & Son brands; and manufactures mouthpieces and distributes accessories, such as music stands, batons, mallets, straps, mutes, reeds, pads, chin rests, strings, bows, cases, and instrument care products. This segment sells its products to students, amateur and professional musicians, and institutions through independent musical instrument dealers and distributors primarily in the United States, Europe, Latin America, and Asia. The company, formerly known as Selmer Industries, Inc., was founded in 1993 and is based in Waltham, Massachusetts.

Advisors’ Opinion:

  • [By Eric Volkman]

    Steinway Musical Instruments (NYSE: LVB  ) has ceased to be the owner of its iconic Steinway Hall in New York City. The company formally closed a deal to sell the building to a partnership headed by real estate concern JDS Development Group. Steinway received $46.3 million in the acquisition, and will recognize a taxable gain of roughly $22 million.

10 Best Building Product Stocks To Buy For 2014: Occidental Petroleum Corporation(OXY)

Occidental Petroleum Corporation, together with its subsidiaries, operates as an oil and gas exploration and production company primarily in the United States. The company operates in three segments: Oil and Gas; Chemical; and Midstream, Marketing, and Other. The Oil and Gas segment explores for, develops, produces, and markets crude oil, natural gas liquids, and condensate and natural gas. Its domestic oil and gas operations are located in Texas, New Mexico, California, Kansas, Oklahoma, Utah, Colorado, North Dakota, and West Virginia; and international oil and gas operations are located in Bahrain, Bolivia, Colombia, Iraq, Libya, Oman, Qatar, the United Arab Emirates, and Yemen. As of December 31, 2010, this segment had proved reserves of approximately 3,363 million barrels of oil equivalent. The Chemical segment manufactures and markets basic chemicals, including chlorine, caustic soda, chlorinated organics, potassium chemicals, and ethylene dichloride products; vinyls, such as vinyl chloride monomer and polyvinyl chloride; and other chemicals comprising chlorinated isocyanurates, resorcinol, sodium silicates, and calcium chloride products. The Midstream, Marketing, and Other segment gathers, treats, processes, transports, stores, purchases, and markets crude oil that includes natural gas liquids and condensate, as well as natural gas and carbon dioxide. This segment also involves in the power generation; and trades around its assets comprising pipelines and storage capacity, as well as oil and gas, other commodities, and commodity-related securities. Occidental Petroleum Corporation was founded in 1920 and is based in Los Angeles, California.

Advisors’ Opinion:

  • [By Lee Jackson]

    Occidental Petroleum Corp. (NYSE: OXY) had a huge day when the company announced that it was spinning off its California assets into a separate company. Occidental has faced calls from Wall Street and activist investors to split its U.S. business from its international operations, with analysts valuing the assets between $19 billion and $22 billion. The fact that the company is not an integrated is seen as a huge positive. Without refining or midstream operations, independent exploration and production majors like Occidental will see the full benefit of rising oil prices in their future results. In an unlikely but not out of the question scenario, the company could also be a takeover target, but it would come with a very steep price tag. Investors receive a very solid 3.0% dividend. The consensus price objective is $107.20. Shares closed Thursday at $92.93.

  • [By MONEYMORNING]

    That’s why we’ve recommended such companies as Occidental Petroleum Corp. (NYSE: OXY), General Electric Co. (NYSE: GE), and E I Du Pont De Nemours & Co. (NYSE: DD).

  • [By Marc Bastow]

    Oil, gas, and chemicals company Occidental Petroleum (OXY) raised its quarterly dividend 12.5% to 72 cents per share, payable April 15 to shareholders of record as of March 10.
    OXY Dividend Yield: 3.02%

10 Best Building Product Stocks To Buy For 2014: Kroton Educacional SA (KROT3)

Kroton Educacional SA (Kroton), formerly Opportunity Officepar Participacoes SA, is a Brazil-based company active in the private education sector. The Company and its subsidiaries are engaged in the management of preschool, elementary, secondary and college preparatory schools, as well as higher, professional and post-graduation education, courses and other related educational activities. In addition, it is involved in the wholesale, retail, distribution, import and export of textbooks, course books, magazines and other publications related to preschool, elementary, secondary and adult education, as well as higher, professional and post-graduation education. Kroton operates in both the On-Campus and Distance Learning business, primarily through its 53 Postsecondary units and 447 active Undergraduate Distance Learning centers, as well as cooperates with approximately 800 Associated Schools in basic education. Advisors’ Opinion:

  • [By Ney Hayashi]

    Anhanguera Educacional Participacoes SA (AEDU3) tumbled after Brazil’s antitrust regulator signaled it may limit the education company’s merger with competitor Kroton Educacional SA. (KROT3) Lojas Renner SA (LREN3) led retailers higher after a report showed Brazil’s industrial production expanded faster than expected in October, easing concern that growth is faltering.